{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:40:00Z","timestamp":1792834800407,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcpo.2026.100823","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:21:58Z","timestamp":1792333318000},"page":"100823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose Optimization of Immune Checkpoint Inhibitors: A Policy opportunity to reduce costs and improve access to immunotherapy in the United States"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-1317","authenticated-orcid":false,"given":"Sameer","family":"Deshmukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthi","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilansh","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-4414","authenticated-orcid":false,"given":"Chelsee J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5486-7748","authenticated-orcid":false,"given":"Scott A.","family":"Soefjie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-2764","authenticated-orcid":false,"given":"Krishna","family":"Sajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M. Qasim","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcpo.2026.100823_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.jcpo.2026.100823_bib2","unstructured":"Cancer Immunotherapy Market Size | Industry Report, 2030 [Internet]. [cited 2025 Jun 28]. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/cancer-immunotherapy-market."},{"key":"10.1016\/j.jcpo.2026.100823_bib3","unstructured":"Read 9 Min, BioSpace [Internet], 2024 [cited 2025 Jun 28]. Cancer Immunotherapy Market Size to Increase USD 280.11 BN by 2033. Available from: https:\/\/www.biospace.com\/cancer-immunotherapy-market-size-to-increase-usd-280-11-bn-by-2033."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44923","article-title":"Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.jcpo.2026.100823_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.jcpo.2026.100823_bib6","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.22.01799","article-title":"Financial toxicity in cancer care: implications for clinical care and potential practice solutions","volume":"41","author":"Khan","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5_suppl","key":"10.1016\/j.jcpo.2026.100823_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.5_suppl.90","article-title":"Real-world evidence data (RWED) of financial toxicity (FT) in patients (pts) receiving cancer immunotherapy treatments","volume":"38","author":"Vorobiof","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.jcpo.2026.100823_bib8","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1212631","article-title":"At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy","volume":"94","author":"Callahan","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"7528","key":"10.1016\/j.jcpo.2026.100823_bib10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib11","first-page":"406","article-title":"A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors","volume":"3","author":"Zielinski","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"issue":"19","key":"10.1016\/j.jcpo.2026.100823_bib12","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib13","article-title":"Alternative dosing strategies for immune checkpoint inhibitors","author":"McGinnis","year":"2022","journal-title":"ILCN.org (ILCN\/WCLC) [Internet]"},{"key":"10.1016\/j.jcpo.2026.100823_bib14","series-title":"NCCN Guidelines NSCLC [Internet]","author":"Riely","year":"2025"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13058-024-01832-7","article-title":"Reporting on patient\u2019s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review","volume":"26","author":"Van Cauwenberge","year":"2024","journal-title":"Breast Cancer Res. BCR"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1503\/cmaj.091481","article-title":"Is bigger better? An argument for very low starting doses","volume":"183","author":"McCormack","year":"2011","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100823_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.01711","article-title":"Cost savings and increased access with ultra-low-dose immunotherapy","volume":"41","author":"Mitchell","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jcpo.2026.100823_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2639","article-title":"Improving tolerability of pembrolizumab with weight based dosing: a meta-analysis","volume":"39","author":"Patail","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-021-01182-3","article-title":"Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?","volume":"15","author":"Maritaz","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib20","series-title":"Study in India Could Make Immunotherapy More Affordable Worldwide [Internet]","author":"Jaber","year":"2022"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100823_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.22.01015","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.02.016","article-title":"Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact?","volume":"113","author":"Bayle","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100823_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1078155220929756","article-title":"A real-world data approach to determine the optimal dosing strategy for pembrolizumab","volume":"27","author":"Jang","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100823_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cllc.2020.05.008","article-title":"Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung cancer","volume":"21","author":"Chiang","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jcpo.2026.100823_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.jcpo.2026.100823_bib26","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100823_bib27","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/psp4.12140","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma","volume":"6","author":"Chatterjee","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"21","key":"10.1016\/j.jcpo.2026.100823_bib29","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib30","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"7","key":"10.1016\/j.jcpo.2026.100823_bib31","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100823_bib32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","author":"Hui","year":"2017","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ijc.33534","article-title":"Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer","volume":"149","author":"Low","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/CRST.CRST_29_19","article-title":"Low doses in immunotherapy: are they effective?","volume":"2","author":"Patil","year":"2019","journal-title":"Cancer Res. Stat. Treat."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00280-019-03954-8","article-title":"Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting","volume":"84","author":"Morrissey","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib36","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00280-019-03971-7","article-title":"Alternative dosing regimens for atezolizumab: right dose, wrong frequency","volume":"84","author":"Goldstein","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jcpo.2026.100823_bib37","unstructured":"Centers for Medicare & Medicaid Services Data [Internet], [cited 2025 Jun 28]. Medicare Part B Drug Spending Dashboard. Available from: https:\/\/data.cms.gov\/tools\/medicare-part-b-drug-spending-dashboard."},{"key":"10.1016\/j.jcpo.2026.100823_bib38","unstructured":"Pemrbolizumab KEYTRUDA FDA Label [Internet], [cited 2025 Jun 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"10.1016\/j.jcpo.2026.100823_bib39","unstructured":"Nivolumab FDA Label.pdf [Internet], [cited 2025 Jun 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125554s112lbl.pdf."},{"key":"10.1016\/j.jcpo.2026.100823_bib40","unstructured":"Atezolizumab FDA Label.pdf [Internet], [cited 2025 Jun 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761034s043lbl.pdf."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib41","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.2888","article-title":"Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center","volume":"9","author":"Hall","year":"2020","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100823_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx063","article-title":"A Phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer","volume":"109","author":"Goldstein","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"31","key":"10.1016\/j.jcpo.2026.100823_bib43","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.18.00045","article-title":"Time is money: optimizing the scheduling of nivolumab","volume":"36","author":"Ratain","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107950","article-title":"Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective","volume":"196","author":"Grit","year":"2024","journal-title":"Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.jcpo.2026.100823_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2509","article-title":"Phase III randomized study comparing ultra-low dose immunotherapy to standard cytotoxic chemotherapy for solid tumors in second line and beyond setting (DELII: Development of Low dose Immunotherapy in India)","volume":"43","author":"Noronha","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib46","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1315","article-title":"1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial","volume":"35","author":"Heuvel","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100823_bib47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40262-025-01610-4","article-title":"Model-based alternative dosing strategies for subcutaneous nivolumab to improve cost effectiveness","volume":"65","author":"Wang","year":"2026","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100823_bib48","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.2022.15268","article-title":"New reforms to prescription drug pricing in the us: opportunities and challenges","volume":"328","author":"Hwang","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100823_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40273-016-0458-0","article-title":"A review of US drug costs relevant to medicare, medicaid, and commercial insurers post-affordable care act enactment, 2010\u20132016","volume":"35","author":"McRae","year":"2017","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jcpo.2026.100823_bib50","author":"Commissioner","year":"2024","journal-title":"FDA [Internet]"},{"key":"10.1016\/j.jcpo.2026.100823_bib51","unstructured":"Regimens | Cancer Care Ontario [Internet], [cited 2026 Oct 3]. Available from: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens?afd_azwaf_tok=eyJraWQiOiJBQTFBOUFGMTM1QUU0NDI0RDgyN0I1M0MwOUYyRDA4N0JCRTQxMjRENDE4MDNFMzY5NkYwMUYwQjk2NUU4RTUzIiwiYWxnIjoiUlMyNTYifQ.eyJhdWQiOiJ3d3cuY2FuY2VyY2FyZW9udGFyaW8uY2EiLCJleHAiOjE3OTEwODgyNzgsImlhdCI6MTc5MTA4ODI2OCwiaXNzIjoidGllcjEtNWI1NzViOWZkOS14ejVtdyIsInN1YiI6IjY4LjU3LjE4Ny4xNTIiLCJkYXRhIjp7InR5cGUiOiJpc3N1ZWQiLCJyZWYiOiIyMDI2MTAwNFQwNDMxMDhaLTE1YjU3NWI5ZmQ5eHo1bXdoQzFCTDE0ZHBjMDAwMDAwMjI3ZzAwMDAwMDAwNXgxayIsImIiOiJ1Y3RHOVN0VzktMkdZYVBQSW5KSjZidVZPSlRWVl85S2tCQy1XdHhUcUFrIiwiaCI6IjhmYlFhNEViZFR4d1JRMEN4V19oamNmR0RsQXRiVVNPNzFLUlVPV016VVUifX0.Eaq7chxAS-9LZEHYIHetGUcpjba18ExTzUSJfJMqQ97a0OAXd_sli3NP0rgAqm_PlXdz-13RzZsbnll2vrQ8wEjdSZu4h-OBVmy5rETFv_jD7mAYOx5cLO351lHxzhzPLFxpjzYvGt1Q61OVjsOh6t3BaTPWja36fnlcEyqUcBkip728zJJEDVSX0-J-Z3aBVMSFL2x0gyx871x_gkApCFpihT4i_HYk2ryAmCsDZwbnNTOmPHGvj-1SQnC1DcBZSM8JXdy_5ok2-eHTw4720YFiYyfGEaruH_J7lIYQO6mGO4MDVQdhYXPt1lKOsf6lSd6BoUpJPGObclRl0XebNg.WF3obl2IDtqgvMFRqVdYkD5s."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100823_bib52","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-25-01546","article-title":"Efficacy and safety of ultra-low-dose immunotherapy in relapsed refractory solid tumors: phase III superiority randomized trial (DELII)","volume":"44","author":"Noronha","year":"2026","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100823_bib53","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.annonc.2025.12.015","article-title":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)","volume":"37","author":"Arora","year":"2026","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00496","article-title":"Comparable effectiveness of weight-based and fixed-dose pembrolizumab in non-small cell lung cancer: insights from a national real-world cohort","author":"Shachar","year":"2026","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.jcpo.2026.100823_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1766420","article-title":"Real-world evidence of lower-dose intensity of immune checkpoint inhibitors in MSI-H\/dMMR gastrointestinal cancers from a resource-constrained setting","volume":"16","author":"Mourad","year":"2026","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100823_bib56","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1007\/s00277-024-06098-9","article-title":"Optimizing resources: low-dose nivolumab combinations in the management of relapsed\/refractory Hodgkin lymphoma","volume":"103","author":"Colunga-Pedraza","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-50526-x","article-title":"Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients","volume":"16","author":"Cengiz","year":"2026","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100823_bib58","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.mayocp.2023.10.012","article-title":"Discarded treatments: when the problem and the solution are more than meets the eye","volume":"98","author":"Sandahl","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jcpo.2026.100823_bib59","unstructured":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Implications of Discarded Weight-Based Drugs. Medications in single-dose vials: implications of discarded drugs [Internet], in: S.J. Nass, T.A. Lustig, F.K. Amankwah, E.H. Shortliffe (eds.): National Academies Press (US), Washington (DC), 2021 [cited 2025 Jun 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569389\/ (PubMed PMID: 33822563)."},{"key":"10.1016\/j.jcpo.2026.100823_bib60","unstructured":"Safe Use of Single Dose\/Single Use Medications to Prevent Healthcare-associated Infections | CMS [Internet], [cited 2025 Aug 11]. Available from: https:\/\/www.cms.gov\/Medicare\/Provider-Enrollment-and-Certification\/SurveyCertificationGenInfo\/Policy-and-Memos-to-States-and-Regions-Items\/Survey-and-Cert-Letter-12-35."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100823_bib61","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11096-022-01388-6","article-title":"An economic evaluation of vial sharing of expensive drugs in automated compounding","volume":"44","author":"Baan","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jcpo.2026.100823_bib62","unstructured":"Sen. Durbin R.J., [D I. S.551 - 116th Congress (2019-2020): REFUND Act of 2019 [legislation] [Internet], 2019 [cited 2025 Aug 11]. Located at: 2019-02-25. Available from: https:\/\/www.congress.gov\/bill\/116th-congress\/senate-bill\/551."},{"key":"10.1016\/j.jcpo.2026.100823_bib63","unstructured":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet [Internet], [cited 2026 Oct 3]. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(19)30650-6\/fulltext."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100823_bib64","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/OP-25-00955","article-title":"Subcutaneous immunotherapy in cancer: where we are now, what it changes, and what to watch next","volume":"22","author":"Petrelli","year":"2026","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.jcpo.2026.100823_bib65","article-title":"Efficacy and safety of subcutaneous versus intravenous administration of PD-1\/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis","volume":"16","author":"Wu","year":"2026","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100823_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-021-01654-3","article-title":"Optimized dosing: the next step in precision medicine in non-small-cell lung cancer","volume":"82","author":"Boosman","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jcpo.2026.100823_bib67","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/S1470-2045(23)00095-5","article-title":"REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment","volume":"24","author":"Ghorani","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100823_bib68","unstructured":"Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial), [Internet], [cited 2025 Jun 28]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-001707-32\/NL."},{"key":"10.1016\/j.jcpo.2026.100823_bib69","unstructured":"Radboud University Medical Center, Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for Non-small Cell Lung Carcinoma [Clinical trial registration] [Internet]. clinicaltrials.gov, 2024 Apr [cited 2025 Jun 28]. Clinical trial registration no.: NCT04909684. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04909684."},{"key":"10.1016\/j.jcpo.2026.100823_bib70","unstructured":"University of Chicago, A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers [Clinical trial registration] [Internet], clinicaltrials.gov, 2024 [cited 2025 Jun 28]. Clinical trial registration no.: NCT04295863. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04295863."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:29:01Z","timestamp":1792834141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326001244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":70,"alternative-id":["S2213538326001244"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100823","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose Optimization of Immune Checkpoint Inhibitors: A Policy opportunity to reduce costs and improve access to immunotherapy in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100823","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100823"}}